{
    "root": "cb9e8049-c3d3-466e-bf9c-3c5032030f4e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "budesonide",
    "value": "20250310",
    "ingredients": [
        {
            "name": "BUDESONIDE",
            "code": "Q3OKS62Q6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3207"
        },
        {
            "name": "ACETYLTRIBUTYL CITRATE",
            "code": "0ZBX0N59RZ"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "budesonide delayed-release capsules corticosteroid indicated : \u2022 treatment mild moderate active crohn 's disease involving ileum and/or ascending colon , patients 8 years older . ( 1.1 ) \u2022 maintenance remission mild moderate crohn 's disease involving ileum and/or ascending colon 3 months adults . ( 1.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "instructions ( 2.1 ) \u2022 take daily morning . \u2022 swallow whole . chew crush . \u2022 patients unable swallow intact capsule , open capsules empty granules onto one tablespoonful applesauce . mix consume entire contents within 30 minutes . chew crush . follow 8 ounces water . \u2022 avoid consumption grapefruit juice duration therapy . recommended mild moderate active crohn 's disease ( 2.2 ) \u2022 adults : 9 mg daily 8 weeks ; repeat 8 week treatment courses recurring episodes active disease . \u2022 pediatrics 8 17 years weigh 25 kg : 9 mg daily 8 weeks , followed 6 mg daily morning 2 weeks . maintenance remission mild moderate crohn 's disease ( 2.3 ) \u2022 adults : 6 mg daily 3 months ; taper complete cessation 3 months . continued treatment 3 months shown provide substantial benefit . \u2022 switching oral prednisolone , begin tapering prednisolone concomitantly initiating budesonide delayed-release capsules . hepatic impairment \u2022 consider reducing 3 mg daily adult patients moderate hepatic impairment ( child-pugh class b ) . ( 2.4 , 5.1 , 8.6 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "hypersensitivity budesonide ingredients budesonide delayed-release capsules . ( 4 )",
    "indications_original": "Budesonide delayed-release capsules are corticosteroid indicated for: \u2022 Treatment of      mild to moderate active Crohn's disease involving the ileum and/or the      ascending colon, in patients 8 years and older. ( 1.1 ) \u2022 Maintenance of      clinical remission of mild to moderate Crohn's disease involving the      ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 )",
    "contraindications_original": "Administration Instructions ( 2.1 ) \u2022 Take once daily in the morning. \u2022 Swallow whole. Do not chew or crush. \u2022 For patients unable to swallow an intact      capsule, open the capsules and empty the granules onto one tablespoonful      of applesauce. Mix and consume the entire contents within 30 minutes. Do      not chew or crush. Follow with 8 ounces of water. \u2022 Avoid consumption of grapefruit juice for      the duration of therapy. Recommended Dosage Mild to moderate active Crohn's disease ( 2.2 ) \u2022 Adults: 9 mg once daily for up to 8      weeks; repeat 8 week treatment courses for recurring episodes of active      disease. \u2022 Pediatrics 8 to 17 years who weigh more      than 25 kg: 9 mg once daily for up to 8 weeks, followed by 6 mg once daily      in the morning for 2 weeks. Maintenance of clinical remission of mild to moderate Crohn's disease ( 2.3 ) \u2022 Adults: 6 mg once daily for up to 3 months; taper to complete cessation after 3 months. Continued treatment for more than 3 months has not been shown to provide substantial clinical benefit. \u2022 When switching from oral prednisolone, begin tapering prednisolone concomitantly with initiating budesonide delayed-release capsules. Hepatic Impairment \u2022 Consider reducing the dosage to 3 mg once daily in adult patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.4 , 5.1 , 8.6 )",
    "adverseReactions_original": "Hypersensitivity to budesonide or any of the ingredients in budesonide delayed-release capsules. ( 4 )",
    "drug": [
        {
            "name": "budesonide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3207"
        }
    ]
}